Aug 2026· Molecular Pharmaceutics· 0 citations· 45 references
TL;DR
An OpenAI-based framework was developed to systemically analyze terminated trials on ClinicalTrials.gov and may provide a new direction to apply AI technologies for drug development, and inspire future investigations of clinical reports and public information from the perspective of delivery technology applications.
Abstract
Numerous drug candidates showed great promise in experimental and preclinical investigations but failed in clinical trials. One cause to this problem may be nonspecific drug biodistribution, leading to adverse effects in healthy organs. Drug delivery technologies are developed to overcome this exact problem by navigating drugs more selectively to the disease sites. Therefore, they hold the promise to revive at least some failed drugs. However, it is challenging to identify such candidates revivable by drug delivery: first, there lacks systemic survey and documentation of drug biodistribution in patients during the trials; second, clinical trial results, especially the failed ones, are often reported in unstructured and/or inconsistent language. Here, we harnessed the recent advances in artificial intelligence (AI) agents and large language models (LLMs) to tackle with the second problem. An OpenAI-based framework was developed to systemically analyze terminated trials on ClinicalTrials.gov. This framework integrated structured extraction of clinical trial information, disease-site inference with evaluation based on predefined screening criteria, which is unwanted biodistribution (UB failure) reflected by the difference in the anatomical locations between adverse effects and targeted diseases. We also paired this with the analysis of drug types and physicochemical properties (e.g. molecular weight and hydrophobicity). Using a validation set, the model achieved accuracies of 89.69% for UB failure classification, 91.75% for small molecule drug classification, and 88.66% for hydrophobicity classification. We then applied this analysis to all terminated ClinicalTrials.gov trials, which identified 817 trials possibly failed due to UB, and top ten small molecule drugs likely suitable for our peptide-guided delivery platform. Overall, this study may provide a new direction to apply AI technologies for drug development, and inspire future investigations of clinical reports and public information from the perspective of delivery technology applications.
A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.
The potential of artificial intelligence in drug discovery and development, has been explored in this review, encircling several stages from identification of target to its clinical applications, followed by drug development approaches encompassing the future of artificial intelligence in the pharmaceutical sector.
Diptanu De, Sohini Chakraborty, Satarupa Banerjee· Frontiers in Oncology· 0 citations
The conventional drug discovery pipeline is resource-intensive, time-consuming, and characterized by high attrition rates, often requiring more than a decade and billions of dollars to bring a single therapeutic agent to market. Drug repurposing identifying new therapeutic indications for approved or investigational dr...
Z. Malik, Kamran Ahmad, Sheheryar Ahmed· Computational biology and ch...· 0 citations
The Virtual Biotech is introduced, an organization of artificial intelligence agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development, which demonstrates its utility at three drug-development decision points.
Harrison G. Zhang, P. Eckmann, Jia-Cheng Miao et al.· Science· 0 citations
Artificial intelligence (AI) and machine learning (ML) provide powerful computational tools for integrating heterogeneous biomedical data and identifying clinically relevant drug-disease and drug-target relationships. The present review focuses on an AI-driven drug repurposing methodology for selecting lead combination...
K. Rashmi, Pushpendra Kumar, Ujjwal et al.· GLOBAL JOURNAL OF PHARMACEUT...· 0 citations
This comprehensive review examines the state-of-the-art applications of LLMs across the drug development pipeline, spanning target identification, molecular generation, property prediction, and drug repurposing in drug discovery, as well as clinical decision support, patient stratification, treatment personalization, a...
Hasi Hays, William J. Richardson· Frontiers in Drug Discovery· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.